The role of calcimimetics in chronic kidney disease

Kidney International

Volumn 70, Issue SUPPL. 104, 2006, Pages

  Gal Moscovici, A ^a,b   Sprague, S M ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

Calcium sensing receptor; Cinacalcet; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; CINACALCET; PHOSPHATE; PHOSPHATE BINDING AGENT; R 568; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIALYSIS; HUMAN; HYPOCALCEMIA; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; VOMITING;

EID: 33751071578     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001982     Document Type: Article

References (34)

1. Feinfeld DA, Sherwood LM. Parathyroid hormone and 1,25(OH)2D3 in chronic renal failure. Kidney Int 1988; 33: 1049-1058. review.
2. Takahashi F, Denda M, Finch JL et al. Hyperplasia of the parathyroid gland without secondary hyperparathyroidism. Kidney Int 2002; 61: 1332-1338.
3. Slatopolsky E. The role of calcium, phosphorus and vitamin D metabolism in the development of secondary hyperparathyroidism. Nephrol Dial Transplant 1998; 13(Suppl 3): 3-8.
4. Nemeth EF. Pharmacological regulation of parathyroid hormone secretion. Curr Pharm Des 2002; 8: 2077-2087. review.
5. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-1121.
6. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(Suppl 3): S112-S119.
7. Block GA, Klassen PN, Lazarus PM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
8. Smith AJ, Faugere MC, Abreo K et al. Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis. Am J Nephrol 1986; 6: 275-283.
9. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021.
10. Sprague SM, Llach F, Amdahl M et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-1490.
11. Nemeth EF, Steffey ME, Hammerland LG et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998; 95: 4040-4045.
12. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800-807.
13. 2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 1998; 53: 1083-1088.
14. Mizobuchi M, Hatamura I, Ogata H et al. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 2004; 15: 2579-2587.
15. Fox J, Lowe SH, Conklin RL et al. Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats. J Pharmacol Exp Ther 1999; 290: 480-486.
16. Wada M, Nagano N, Furuya Y et al. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 2000; 57: 50-58.
17. Wada M, Ishii H, Furuya Y et al. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998; 53: 448-453.
18. Ishii H, Wada M, Furuya Y et al. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 2000; 26: 175-182.
19. Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1232-1237.
20. Henley C, Colloton M, Cattley RC et al. 1,25-dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1370-1377.
21. Lopez I, Aguilera-Tejero E, Mendoza FJ et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006; 17: 795-804.
22. Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int 1998; 53: 223-227.
23. Goodman WG, Frazao JM, Goodkin DA et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58: 436-445.
24. Goodman WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 1017-1024.
25. Drueke TB, Cunningham J, Goodman WG et al. Short term treatment of secondary hyperparaathyroidism with the calcimimetic agent AMG 073 [abs.A3992]. J Am Soc Nephrol 2001; 12: 764A.
26. Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14: 575-583.
27. Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63: 248.
28. Block GA, Coyne DW, Goodman WG et al. The calcimimetic AMG 073: a potential novel therapy for secondary hyperparathyroidism [abst SU-P0509]. J Am Soc Nephrol 2002; 13: 572A.
29. De Francisco ALM, Surayi M, Cunningham J et al. Oral cinacalcet HCl (AMG 073)for the treatment of dialysis patients with secondary hyperparathyroidism: results of a European/Australian phase III study [abst SA-P0742]. J Am Soc Nephrol 2003; 14: 461A.
30. Block GA, Martin KJ, Turner SA et al. Phase 3 study results demonstrate efficacy and safty of the calcimimetic cinacalcet HCl in hemodialysis patients with secondary hyperparathyroidism.[abst SA-P0743]. J Am Soc Nephrol 2003; 14: 461A.
31. Lindenberg JC, Culleton B, Wong G et al. Phase 3 experience with cinacalcet HCl in hemodialysis and peritoneal dialysis patients with secondary hyperparathyroidism. [abst SA-P0752]. Am Soc Nephrol 2003; 14: 463A.
32. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760-771.
33. Charytan C, Coburn JW, Chonchol M et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 2005; 46: 58-67.
34. Moe SM, Cunningham J, Bommer J et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet Hcl. Nephrol Dial Transplant 2005; 20: 2186-2193.